 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Angiotech Pharmaceuticals, Inc.
 |
Angiotech Pharmaceuticals, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Single stock futures make U.S. debut, in theory Aug 21 2001 03:52 PM PDT
Bank Austria says Holocaust fund fully effective Aug 21 2001 09:27 AM PDT
Angiotech stock climbs after distribution deal Aug 21 2001 09:26 AM PDT
Angiotech posts loss, cites strong Canadian dollar Aug 14 2001 01:26 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Angiotech Pharmaceuticals is teaching an old drug new tricks. The company is developing products based on paclitaxel, the successful anticancer drug developed in the 1960s. Angiotech will take advantage of paclitaxel's anti-inflammatory properties to make drugs to treat rheumatoid arthritis, multiple sclerosis, and psoriasis. Angiotech will also make surgical products coated with paclitaxel, which will help prevent restenosis (scarring) after vascular, ophthalmic, and potentially other kinds of surgery. The company's revenue comes from license, option, and research fees; it partners with firms like Boston Scientific, C. R. Bard, and Cook, Inc. Chairman and CEO Dr. William Hunter founded the company in 1992.
COMPETITION |
 |
DRAXIS Health Inc. (DRAX)
IVAX Corporation (IVX)
NeoPharm, Inc. (NEOL)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 3.00
1-Yr. Sales Growth: 36.4%
Employees: 47
Revenue per employee: $63,829.79
KEY PEOPLE |
 |
William Hunter
CEO
David M. Hall
CFO
CONTACT INFO |
 |
6660 NW Marine Dr.
Vancouver British Columbia V6T 1Z4, Canada
Phone: 1-604-221-7676
Fax: 1-604-221-2330
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |